This partnership is a continued demonstration of Jubilant ™s global partnering efforts to identify and deliver affordable and enabling innovation and health care solutions to the global pharmaceutical industry and patients worldwide. Duke Medicine is the ideal academic health sciences partner for us to pursue our intent of building a world-class research capability as an overlay to our network of healthcare facilities that provide high quality, low cost care for economically weaker section and rural communities in India, said Shyam Bhartia, Chairman & Managing Director & Hari Bhartia, Co-chairman and Managing Director for Jubilant Organosys. Duke University uniquely understands the importance of eliminating global health disparities and is recognized globally for its excellence in conducting translational research that will, in this case, help us work together towards improving the high quality and affordable care for patients in India.

"I believe academic health sciences centers have the ability and the collective responsibility to transform medicine, improve health and reduce health disparities locally and globally, said Dzau. However, achievement of these goals necessitates the development of a continuum that spans discovery and translation sciences, and must include optimal partnerships that are not limited by geography. Partnerships with like-minded leading global healthcare entities, such as Jubilant, will be critically important in making this possible.

The Duke Translational Medicine Institute (DTMI) and the Office of Licensing and Ventures (OLV) will coordinate the translational research component of this partnership for Duke University, while the Duke Global Health Institute (DGHI) will coordinate the cohort studies component.

Source: Duke University